Dr. Andrew Leavitt is director of UCSF's program for noncancerous blood disorders as well as co-director of the UCSF Hemophilia Treatment Center. He cares for patients with nonmalignant blood diseases, including bleeding disorders (such as hemophilia and von Willebrand disease), platelet function disorders, disorders of insufficient platelets, venous thromboembolic disorders (which involve blood clots), neutropenia (reduced numbers of the white blood cells called neutrophils) and anemia.

Leavitt is medical director of UCSF's laboratory for blood and marrow transplant research. He is internationally known for his studies of the development of megakaryocytes, large cells in the bone marrow that divide to produce blood platelets. His research also focuses on improving treatment and outcomes for patients with venous thromboembolic diseases.

Leavitt obtained his medical degree at Harvard Medical School. He completed a residency in internal medicine and served as chief resident at the University of Michigan. At UCSF, he completed a fellowship in hematology and oncology, followed by a fellowship in transfusion medicine. He joined the UCSF faculty in 1992.

Leavitt has served on the editorial boards of Blood and the Journal of Clinical Investigation. He currently serves on the editorial board of the Journal of Clinical and Translational Science.

  • Education

    Harvard School of Medicine, 1984

  • Residencies

    University of Michigan Hospital, Internal Medicine, 1988

  • Fellowships

    UCSF Medical Center, Transfusion Medicine, 1992

    UCSF Medical Center, Hematology/Oncology, 1991

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

  • Academic Title

    Professor

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

Hemophilia Treatment Center

400 Parnassus Ave., 4th Floor
San Francisco, CA 94143

Decorative Caduceus

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile. The study drug is identified as AAV5-hFIXco-Padua (AMT- 061)....

Recruiting

Decorative Caduceus

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophili...

This clinical trial is being conducted to learn more about a potential treatment (valoctocogene roxaparvovec) for people with severe hemophilia A. This research study will test and confirm the safety and effectivenes...

Recruiting

Decorative Caduceus

Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Se...

The purpose of the study is to evaluate the safety, tolerability and time-course profile of FVIII activity levels with adaptive doses of SB-525.

Recruiting

Share